Stephens Inc. AR Cuts Stock Position in Zoetis Inc. $ZTS

Stephens Inc. AR cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 15.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 108,583 shares of the company’s stock after selling 20,505 shares during the quarter. Stephens Inc. AR’s holdings in Zoetis were worth $12,836,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis in the 4th quarter worth $25,000. Prosperity Bancshares Inc acquired a new position in shares of Zoetis during the fourth quarter worth about $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis during the third quarter worth about $31,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis in the fourth quarter valued at about $30,000. Finally, Elyxium Wealth LLC purchased a new stake in Zoetis in the 4th quarter valued at approximately $32,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In related news, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the transaction, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 11,650 shares of company stock valued at $886,384 over the last quarter. Corporate insiders own 0.22% of the company’s stock.

Zoetis Price Performance

ZTS traded up $1.61 during trading on Tuesday, reaching $77.03. 1,163,568 shares of the stock were exchanged, compared to its average volume of 5,615,322. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The company has a market capitalization of $32.29 billion, a price-to-earnings ratio of 12.80, a P/E/G ratio of 1.17 and a beta of 0.75. Zoetis Inc. has a 1 year low of $71.47 and a 1 year high of $161.77. The business’s 50 day moving average price is $84.04 and its two-hundred day moving average price is $109.31.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. Zoetis’s payout ratio is presently 35.16%.

Analysts Set New Price Targets

Several research firms have recently commented on ZTS. Morgan Stanley reissued an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a report on Friday, May 15th. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Stifel Nicolaus cut their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research report on Friday, June 26th. UBS Group reduced their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Finally, Barclays lowered their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus price target of $123.46.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.